We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]
Novo Holdings, a leading healthcare investment firm, announced today its acquisition of KabaFusion (the “Company”), a leading national provider of home infusion therapies, from Pritzker Private Capital (“PPC”), a leader in family direct investing. Terms of the transaction were not disclosed. Read more here.
Funds will be used to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities Plans to expand platform beyond hemophilia A 02 November 2022, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million in a Series A financing […]
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]
Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.